Breakthrough treatments can change a disease. They can also distort the public conversation if the word “cure” makes everyone assume the problem is finished. Sickle cell patients still have to navigate pain crises, emergency rooms, insurance, specialist shortages and clinicians who may not understand—or believe—the severity of their symptoms.

That is why patient-centered advocacy matters even in an era of exciting science. A therapy can be technically available and practically unreachable because of cost, eligibility, geography or the demands of treatment. People who are not candidates for a new therapy still deserve excellent care now.

Sickle cell has long exposed the consequences of racial inequity in medical research and treatment. The disease disproportionately affects people of African descent, yet patients have described years of undertreatment and suspicion around pain medication. New science should not erase that history; it should make the system more accountable to it.

A medical breakthrough is most meaningful when the people living with the condition remain the center of the story, not the footnote after the headline.